BioCentury
ARTICLE | Finance

Larger and later

Vesalius targeting European late-stage life science companies with third fund

May 19, 2017 9:13 PM UTC

Vesalius Biocapital Partners plans to double down on late-stage investments with its third Europe-focused life sciences fund to provide faster exits for its LPs.

Vesalius Biocapital III, a planned €150 million ($164.1 million) fund, raised €67 million ($73.3 million) in a first close on May 18. The final close is expected next year. ...